COGT - Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting | Benzinga
WALTHAM, Mass. and BOULDER, Colo., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its upcoming posters for bezuclastinib at the 2024 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in Washington, D.C. from February 23-26, 2024. The company will host a virtual investor webcast on Friday, February 23 at 8:00 a.m. ET.
Poster Details
Poster Presentation Title: Initial Results from Summit: An Ongoing, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Session Date and Time: February 25, 2024 – 9:45am – 10:45am ET
Session Title: Mast Cell Disorders
Poster Number: 694
Location: Walter E. Washington Convention Center, Level 2, Hall D; Washington, DC
Poster Presentation Title: Physician and Patient ...